Combining Sodium–Glucose Co‐Transporter‐2 Inhibitor Plus Glucagon‐Like Peptide‐1 Receptor Agonist for Glucose‐Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real‐World Clinical Practice ( CombiKid Study)
Open Access
- 16 June 2026
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (9) , 7950-7963
Abstract
Aims: Sodium–glucose co‐transporter 2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have separately shown renoprotective effects in clinical trials in people with type 2 diabetes. It is unclear whether combining these agents produces incremental kidney outcome benefits. Materials and Methods: Retrospective cohort study with a prevalent new‐user design using pseudonymised data from the Oxford‐Royal College of General Practitioners Research and Surveillance Centre primary care sentinel network. We extracted data for two cohorts prescribed SGLT2is and/or GLP‐1 RAs between January 2013 and December 2021. We 1:1 propensity score matched SGLT2i plus GLP‐1 RA combination users with monotherapy (SGLT2i or GLP‐1RA) users. Multivariable linear regression analyses estimated adjusted mean differences in absolute change in estimated glomerular filtration rate (eGFR) (baseline to 1‐ and 2‐years follow‐up) between combination and monotherapy. Results: Across the matched combination and SGLT2i monotherapy groups ( N = 14 774), mean decline in eGFR, baseline to 1‐year, was −4.5 mL/min/1.73 m 2 and 2‐years, −5.0 mL/min/1.73 m 2 , with no difference when comparing combination and SGLT2i monotherapy. Across the matched combination and GLP‐1 RA monotherapy groups ( N = 14 154), mean decline in eGFR, baseline to 1‐year, was −5.4 mL/min/1.73 m 2 and 2‐years, −6.1 mL/min/1.73 m 2 , but combination therapy was associated with a smaller eGFR reduction compared with GLP‐1 RA monotherapy (difference in eGFR at 1‐year: [mean, 95% confidence interval, CI] 2.2, 1.7 to 2.8, p < 0.001; and at 2‐years: 2.1, 1.4–2.7, p < 0.001). Conclusions: In real‐world clinical practice, the combination of SGLT2i and GLP‐1 RA may be more effective for preserving kidney function than GLP‐1 RA monotherapy. This effect was not seen with combination versus SGLT2i monotherapy.Keywords
This publication has 39 references indexed in Scilit:
- Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studiesDiabetologia, 2025
- GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 InhibitorsJACC: Heart Failure, 2024
- Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protectionAmerican Journal of Preventive Cardiology, 2023
- Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trialDiabetologia, 2023
- Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)Kidney International, 2022
- The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS programInternational Journal of Cardiology, 2020
- Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney diseaseDiabetologia, 2019
- Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibitionDiabetologia, 2016
- Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scoresPharmacoepidemiology and Drug Safety, 2016
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetesDiabetologia, 2011